Press "Enter" to skip to content

Abbott posts strong Q3 results, narrows full year outlook

Pharmaceutical giant Abbott Laboratories (ABT) delivered a 12% increase in third-quarter revenue to $7.7 billion, helped by a 43% increase in diagnostics product sales. The top line surpassed market consensus, which was projected at $7.67 billion.

However, net income from continuing operations fell to $563 million or 31 cents per share, compared to $603 million, or 32 cents per share a year ago. On an adjusted basis, Abbott reported better-than-expected earnings of 75 cents per share, a cent higher than the street expectation.

Abbott Q3 earnings
image courtesy: Open Grid Scheduler

“We achieved another quarter of strong growth and our new product pipeline continues to be highly productive. In spite of increasing currency headwinds, we’re well-positioned to achieve the upper end of our initial full-year guidance,” CEO Miles D. White said in a statement.

The Illinois-based company, meanwhile, narrowed its full-year earnings outlook range on a GAAP basis to $1.33 to $1.35 per share, primarily due to headwinds in the international markets posed by a stronger US dollar.  Excluding one-off items, Abbott expects to earn $2.87 to $2.89 per share.

During the third quarter, sale of Diagnostics products saw the biggest jump of 42.6% to 1.8% billion. The biggest segment, Medical Devices, witnessed a modest 8% growth while the sale of Nutrition products grew 4% during the third quarter.

Abbott posts 17% sales growth for Q2; beats estimates

Abbott shares were down about 2% during pre-market trading on Wednesday.

Follow our Google News edition to get the latest stock market, earnings and financial news at your fingertips. 

Related Articles

Latest Articles

Top
%d bloggers like this: